Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?

Article Details

Citation

Copy to clipboard

Kaisary AV, Iversen P, Tyrrell CJ, Carroll K, Morris T

Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?

Prostate Cancer Prostatic Dis. 2001;4(4):196-203.

PubMed ID

12497018 [ View in PubMed

]

Abstract

Castration is the most widely used form of androgen ablation employed in the treatment of metastatic (M1) prostate cancer. Non-steroidal antiandrogen monotherapy is a potential alternative treatment option for men for whom castration is unacceptable or not indicated. Of the three non-steroidal antiandrogens, bicalutamide ('Casodex'), flutamide and nilutamide, only bicalutamide has been compared with castration in large, controlled, randomised, Phase III trials in M1 patients. A post-hoc analysis of these studies indicated that bicalutamide 150 mg/day monotherapy may be of benefit to M1 patients with a prostate specific antigen (PSA) level 400 ng/ml) may decide that quality of life and symptomatic benefits outweigh the slight survival disadvantage seen in clinical trials and opt for bicalutamide monotherapy as an alternative to castration.Prostate Cancer and Prostatic Diseases (2001) 4, 196-203.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Nilutamide	Androgen receptor	Protein	Humans	Yes	Antagonist	Details